Supporting Information S1 - Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease

This supplemental file contains the following: This supplemental file contains the following: Supporting Materials and Methods. Figure S1: Characterization of the NPs. Figure S2: Caspase-3 mRNA silencing percentage by RT-PCR in SH-SY5Y cells using different caspase-3 shRNA encoding plasmid. Figure S3: In vitro toxicity evaluation by MTT. Figure S4: The body weight changes during rotenone/oil treatment with weekly administration of different NPs. Figures S5 and S6: Immunofluorescence images of activated caspase-3 during the treatment of rotenone for various days with different NPs in different rat brain regions.
(DOC)